Trial Profile
A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Mar 2024
Price :
$35
*
At a glance
- Drugs MT 0169 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Takeda Oncology
- 04 Mar 2024 Results presented in a Molecular Templates media release.
- 12 Jan 2024 Status changed from active, no longer recruiting to discontinued.
- 27 Nov 2023 Status changed from recruiting to active, no longer recruiting.